Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study Correspondence

  

Authors:	Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; Tan, C.; Shah, U.; Devlin, S.; Landgren, O.
Title:	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
Keywords:	clinical article; aged; fatigue; follow up; antineoplastic agent; prospective study; letter; progression free survival; multiple myeloma; antineoplastic combined chemotherapy protocols; maintenance therapy; dexamethasone; high risk patient; acute kidney failure; pilot study; pilot projects; urinary tract infection; comorbidity; lung infection; disease exacerbation; boron compounds; overall response rate; combination drug therapy; smoldering multiple myeloma; humans; human; boron derivative; ixazomib
Journal Title:	Leukemia and Lymphoma
Volume:	63
Issue:	11
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2022-01-01
Start Page:	2760
End Page:	2761
Language:	English
DOI:	10.1080/10428194.2022.2095626
PUBMED:	35838493
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134153206&doi=10.1080%2f10428194.2022.2095626&partnerID=40&md5=fab8221f7c2f59121ad9a058e15fbd56
Notes:	Letter -- Export Date: 1 December 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/200679